Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy (HIFU-AR)

Inclusion Criteria:

• Age ≥ 18 years at the day of consenting to the study.
• Patients with liver metastases requiring a hepatectomy for ≥ 2 segments.
• ECOG PS ≤ 1.

• Adequate bone marrow and liver function at baseline as defined below:

  • Platelet count ≥ 100 x 109/l, and hemoglobin of ≥ 9 g/dl),
  • Total bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN.
• Recovered from prior anti-neoplasic treatment-related toxicity (grade <2 persistent treatment-related toxicity as per CTCAE v4 are accepted).
• Willingness for follow-up visits.
• Covered by a medical insurance.
• Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment.

Exclusion Criteria:

• Patients having previously undergone

  • a major hepatic surgery (i.e. more than 3 liver segments) or
  • biliary major surgery.
• Patient with cirrhosis or sinusoidal obstruction syndrome with portal hypertension.
• Pregnant women (women of childbearing potential are required to have a negative pregnancy test within 72 hours prior to inclusion). A positive urine test must be confirmed by a serum pregnancy test.